A Case Report of Conjunctival Extranodal Marginal Zone Lymphoma Treated with Intralesional Rituximab Injection Therapy.

Titap YaziciogluMurat OklarSeyhan KocabasErdi KaradagVildan ElibolMehmet Engin Tezcan

Published in: Ocular immunology and inflammation (2022)

The intralesional rituximab is a cost-effective and well-tolerated treatment for low-grade conjunctival lymphoma. The intralesional rituximab therapy may be prefer in the patients with low grade conjunctival lymphoma instead of radiotherapy. There will be needed further researches in this area.

Keyphrases

low grade
diffuse large b cell lymphoma
high grade
early stage
chronic lymphocytic leukemia
radiation therapy
stem cells
radiation induced
ultrasound guided
rectal cancer